Retrospective analysis was conducted to evaluate patient characteristics, therapies and outcomes. Patients were grouped based on the PACIFIC trial eligibility criteria for durvalumab. PFS and OS were estimated using the Kaplan-Meier method, and comparisons between subgroups were made using log-rank testing, adjusted by Cox proportional hazards regression. Result: 146 patients completed CRT for locally advanced NSCLC from 2007 to 2018. 27% (n¼40) would be considered ineligible for durvalumab based on the PACIFIC criteria (Table 1: reasons). Patient demographics were similar in ineligible vs. eligible groups: mean age 67.7 vs 67.9 years, male 57.6% vs 43.5%, Black 36.7% vs 43.5%, Hispanic 22.6% vs 30.1%. In the era of durvalumab therapy (since 9/2017), 68% (n¼17) received durvalumab, including 4 patients that did not meet PACIFIC criteria due to comorbidities and/or additional malignancy. The use of durvalumab therapy has increased with time in eligible patients from 33% in 9/ 2017-12/2017 to 100% in 10/2018-12/2018. The median time to initiate durvalumab following CRT has decreased from 56 days before 7/2018 to 30 days afterwards (p¼0.02). Several eligible patients did not receive durvalumab due to questionable benefit in EGFRemutant NSCLC (n¼2), refusal of treatment (n¼1), and unkown (n¼1). Compared to patients who received durvalumab, patients who did not receive it were found to be of a lower socioeconomic status (p¼0.086). Moreover, there was a trend toward improved 15-month OS rates in durvalumab-treated patients compared with patients who did not receive it (100% vs 87.5%, p¼0.131).
Conclusion:Our results reveal more frequent use and improved time to initiate durvalumab following CRT, as well as promising initial survival data in a real world setting. A substantial proportion of patients would be ineligible as per PACIFIC criteria, yet several received durvalumab and remain disease controlled, suggesting that further investigation of durvalumab in this population is warranted.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.